HAVCR2 and breast cancer: After this, mammary tumor–bearing mice received daily doses of anti-ICOS, anti–PD-1, or anti–TIM-3 over 3 d to mitigate the confounding effects of these antibodies on other T cell subsets (Fig. 7 A).